Published in Gene Therapy Weekly, May 17th, 1999
S.I. Miyatake and colleagues from the Kyoto University Hospital, Japan and Georgetown University Medical Center, Washington, DC, analyzed a hepatoma-specific viral vector incorporating the herpes simplex virus (HSV) both in vitro and in vivo ("Hepatoma-Specific Antitumor Activity of an Albumin Enhancer/Promoter Regulated Herpes Simplex Virus In Vivo," Gene Therapy, April 1999;6(4):564-72).
"We describe an alternative approach to virus-mediated gene therapy, where HSV replication and associated cytotoxicity are limited to a specific cell-type by the regulated expression of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1999-05-17)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.